Yale University

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Yale University sits in the top decile of US sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count).

1,492 total trials 254 currently recruiting 1005 completed early-phase tilt top decile by trial count

Yale University: 1,492 sponsored US clinical trials, 254 recruiting.

Yale University sponsors 1,492 registered US clinical trials on ClinicalTrials.gov, 254 of them currently recruiting, and 1,005 completed. 99 of these trials are in Phase 3-4 (later-stage) and 579 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Opioid Use Disorder, with 19 trials.

Top-decile sponsor footprint

Yale University ranks in the top decile of sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 60/100

1,005 of 1,138 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,492 total, page 12 of 30

COMPLETED NA

Comparing a Fatherhood Focused Individual Intervention to Batterer Intervention to Reduce IPV and Child Maltreatment

NCT04165291

COMPLETED NA

CAPO: Continuous Glucose Monitoring in A2 Gestational Diabetes and Pregnancy Outcomes

NCT04219085

COMPLETED NA

Drug-Targeted Alerts for Acute Kidney Injury

NCT02771977

COMPLETED

Real World Use and Outcomes of VASCADE Closure Device Versus Manual Compression in Patients With CFA Disease

NCT04745624

COMPLETED NA

Coordinating Opioid Use Treatment Through Medical Management With Infection Treatment (Project COMMIT)

NCT04180020

TERMINATED Phase 2

Aspirin to Prevent Preeclampsia in Women With Elevated Blood Pressure and Stage 1 Hypertension (ASPPIRE)

NCT04402385

TERMINATED Phase 1

Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD: a Proof-of-concept Tele-health Study of Stimulant-induced Improvement in Neurocognitive Functioning.

NCT04386811

COMPLETED Phase 4

A Smart Approach to Treating Tobacco Use Disorder in Persons Living With HIV

NCT04490057

COMPLETED Phase 4

Postoperative Dexamethasone on Post-Cesarean Pain

NCT04067609

COMPLETED Early Phase 1

Virtual cOaching in Making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES)

NCT03834870

COMPLETED NA

A Novel Tapered Applicator for Vaginal Vault Brachytherapy

NCT04318340

COMPLETED Phase 2

Emergency Department-Initiated Buprenorphine Validation Network Trial

NCT04225598

COMPLETED NA

Intermittent Versus Continuous Enteral Nutrition in Mechanically Ventilated Patients in the Medical Intensive Care Unit

NCT04437264

COMPLETED NA

COVID-19 Vaccine Messaging, Part 1

NCT04460703

COMPLETED NA

SafetyNet Program for Opioid Use Disorder (OUD)

NCT04253782

COMPLETED NA

Preliminary Effectiveness of Remotely Monitored Blood Alcohol Concentration Device as Treatment Modality

NCT04380116

COMPLETED NA

Very Low Carbohydrate Diet as an Adjunctive Therapy for Youth Type 1 Diabetes

NCT04082884

COMPLETED NA

Treatment of Pregnant Women With OUD

NCT04240392

COMPLETED Phase 2

TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer

NCT04166435

COMPLETED

Validation of a Rapid Quantitative Test for Loss of Smell in COVID-19 Subjects

NCT04431908

COMPLETED Phase 2

Camostat Mesylate in COVID-19 Outpatients

NCT04353284

COMPLETED NA

Study of an App to Facilitate Communication With Parents of Febrile Infants

NCT04328909

TERMINATED Phase 2

The Role of Resistant Starch in COVID-19 Infection

NCT04342689

COMPLETED NA

A Trial of Online LGBTQ-affirmative Cognitive Behavioral Therapy to Reduce Depression and Associated Health Risks Among Young Adults

NCT04408469

TERMINATED NA

Patient-centered Approaches to Provider and Adolescent Reproductive Health Communication and Shared Decision-making

NCT03670745

COMPLETED NA

QBSAfe: A Novel Approach to Diabetes Management Focused on Quality of Life, Burden of Treatment, Social Integration and Avoidance of Future Events

NCT04514523

COMPLETED NA

Acute Effects of Vaping Nicotine on Cognition in Young Adults

NCT04901208

COMPLETED Phase 1

BXCL501 for Agitation in Schizophrenia

NCT03708315

COMPLETED Early Phase 1

Imaging Glutamate Release From Alcohol

NCT04159688

TERMINATED NA

Models of Auditory Hallucination

NCT04210557

COMPLETED Early Phase 1

Resuscitative EndoVascular Aortic Occlusion for Maximal Perfusion

NCT03703453

COMPLETED Phase 1

A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL)

NCT04171791

COMPLETED NA

Voiding Diary Video

NCT04233645

COMPLETED NA

Mobile Physical Activity for Type 1 Diabetes

NCT04204733

COMPLETED Early Phase 1

Diluted Insulin in Young Children: Bigger Volumes for Smaller Patients

NCT03666065

COMPLETED NA

Risk EValuation And Its Impact on ClinicAL Decision Making and Outcomes in Heart Failure

NCT03845660

COMPLETED NA

Relief of Symptoms of Post-traumatic Stress for Victims of Gun Violence

NCT03916614

TERMINATED

Promoting Medications for Alcohol Use Disorder on the General Medicine Service

NCT04287790

COMPLETED NA

Cognitive Behavioral Therapy for Adolescent Binge Eating and Loss of Control Eating

NCT04088097

COMPLETED NA

Cooperative Pain Education and Self-management: Expanding Treatment for Real-world Access (COPES ExTRA)

NCT03469505

COMPLETED Phase 2

Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer

NCT04111510

TERMINATED NA

Social Value Training in Toddlers With Elevated Autism Symptoms

NCT03556826

TERMINATED Phase 2

GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia

NCT04051996

TERMINATED NA

Pathogenesis of the Cardiometabolic Risk in Youth With Type 1 Diabetes

NCT04101045

COMPLETED NA

Pilot: Feasibility of Intermittent Enteral Feeding in Ventilated MICU Patients

NCT04164108

COMPLETED Early Phase 1

Smoking by IV Pulsed Nicotine

NCT04488744

COMPLETED NA

Clinical Decision Support to Implement ED-initiated Buprenorphine for OUD

NCT03658642

COMPLETED Phase 4

Examining the Effect of Burosumab on Muscle Function

NCT04146935

COMPLETED NA

Computer Presented and Physical Exercises to Maintain Cognitive Function and Emotional Health in Older Adults

NCT04404621

COMPLETED NA

Blood Glucose Variability and Insulin Action During Menstrual Cycle in Females With Type 1 Diabetes

NCT02693938

← Previous Page 12 of 30 Next →

Phase Distribution

PhaseTrial count
Phase 1 312
Phase 2 267
Phase 3 52
Phase 4 47

What is open in the Yale University pipeline

254 recruiting of 1,492 indexed (17% open); 1,005 completed (67%).

Phase mix: 99 late (III/IV) vs 579 early (I/II) (early-phase heavy).

Top condition: Opioid Use Disorder (19 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Yale University: open-pipeline peers nationwide

Peers matched on 1,492 registered trials and 17% open enrollment, not the therapeutic-area sidebar.

Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,5002,000 5%10%15%20% Total trials Recruiting share Yale UniversityWashington University School of MedicineJohns Hopkins UniversityUniversity of PennsylvaniaNovartis PharmaceuticalsNYU Langone HealthCSL BehringPenn State UniversityUniversity of Hawaii
Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,492 trials (± recruiting share)

Sponsors near 17% open enrollment (± trial volume)

What to do with this Yale University page

1,492 registered trials is a research-attention snapshot, not an endorsement of Yale University or any single study.

  • 254 of Yale University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Opioid Use Disorder is the condition Yale University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Opioid Use Disorder trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Yale University pipeline card: 1,492 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.